Patents by Inventor Hosung Min
Hosung Min has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230312698Abstract: The invention relates to an antibody or an antigen-binding portion thereof that specifically binds to Ang2, blocking Ang2 binding to Tie2 or integrins, or triggering Ang2 clusting and Tie2 signaling activation.Type: ApplicationFiled: August 6, 2021Publication date: October 5, 2023Applicant: Nanjing GenScript Biotech Co., Ltd.Inventors: Yi Jin, Zhongdao Li, Wenshuang Jia, Brian Hosung Min, Weiming Wang
-
Publication number: 20230203554Abstract: Provided are an improved culture process for reducing unwanted culture byproducts when a target protein is produced in a glutamine-free cell culture medium, an improved culture process for producing a target protein in a glutamine-free cell culture medium, or an improved culture process for producing a target protein in a glutamine-free cell culture medium.Type: ApplicationFiled: October 26, 2017Publication date: June 29, 2023Inventors: Joon Tae PARK, Kyung Ju LEE, Joo Song LIM, Hyoung Taek LIM, Yun Jeong HUH, Jae Sun LEE, Hosung MIN
-
Patent number: 10189912Abstract: Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.Type: GrantFiled: January 12, 2017Date of Patent: January 29, 2019Assignee: AMGEN INC.Inventors: Kenneth W. Walker, Yue-Sheng Li, Thomas Charles Boone, George Doellgast, HoSung Min, Jane Talvenheimo, Taruna Arora, Frederick W. Jacobsen
-
Publication number: 20170190793Abstract: Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.Type: ApplicationFiled: January 12, 2017Publication date: July 6, 2017Applicant: AMGEN INC.Inventors: Kenneth W. WALKER, Yue-Sheng LI, Thomas Charles BOONE, George DOELLGAST (DECEASED), HoSung MIN, Jane TALVENHEIMO, Taruna ARORA, Frederick W. JACOBSEN
-
Patent number: 9562108Abstract: Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.Type: GrantFiled: May 22, 2014Date of Patent: February 7, 2017Assignee: AMGEN INC.Inventors: Kenneth W. Walker, Yue-Sheng Li, Thomas Charles Boone, HoSung Min, Jane Talvenheimo, Taruna Arora, Frederick W. Jacobsen
-
Patent number: 9562107Abstract: Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.Type: GrantFiled: May 22, 2014Date of Patent: February 7, 2017Assignee: AMGEN INC.Inventors: Kenneth W. Walker, Yue-Sheng Li, Thomas Charles Boone, George Doellgast, HoSung Min, Jane Talvenheimo, Taruna Arora, Frederick W. Jacobsen
-
Publication number: 20160176926Abstract: The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz2Lz4 wherein z2 is an amino acid residue and z4 is threonyl or isoleucyl. Exemplary molecules comprise a sequence of the formulae (SEQ.?ID.?NO:?100) a1a2a3CDa6La8a9a10Ca12a13a14, (SEQ.?ID.?NO:?104) b1b2b3Cb6Db8Lb10b11b12b13b14Cb16b17b18 (SEQ.?ID.?NO:?105) c1c2c3Cc5Dc7Lc9c10c11c12c13c14Cc16c17c18 (SEQ.?ID.?NO:?106) d1d2d3Cd5d6d7WDd10Ld13d14d15Ld16d17d18 (SEQ.?ID.?NO:?107) e1e2e3Ce5e6e7De9Le11Ke13ce15e16e17e18 (SEQ.?ID?NO:?109) f1f2f3Kf5Df7Lf9f10Qf12f13f14 wherein the substituents are as defined in the specification. The invention further comprises compositions of matter of the formula (X1)a—V1—(X2)b wherein V1 is a vehicle that is covalently attached to one or more of the above TALL-1 modulating compositions of matter.Type: ApplicationFiled: September 21, 2015Publication date: June 23, 2016Inventors: Hosung MIN, Hailing HSU, Fei XIONG
-
Patent number: 9200040Abstract: Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.Type: GrantFiled: January 12, 2012Date of Patent: December 1, 2015Assignee: Amgen Inc.Inventors: Jonathan Daniel Oliner, Hosung Min
-
Patent number: 9139645Abstract: The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz2Lz4 wherein z2 is an amino acid residue and z4 is threonyl or isoleucyl. Exemplary molecules comprise a sequence of the formulae (SEQ. ID. NO: 100) a1a2a3CDa6La8a9a10Ca12a13a14, (SEQ. ID. NO: 104) b1b2b3Cb5b6Db8Lb10b11b12b13b14Cb16b17b18 (SEQ. ID. NO: 105) c1c2c3Cc5Dc7Lc9c10c11c12c13c14Cc16c17c18 (SEQ. ID. NO: 106) d1d2d3Cd5d6d7WDd10Ld13d14d15Ld16d17d18 (SEQ. ID. NO: 107) e1e2e3Ce5e6e7De9Le11Ke13Ce15e16e17e18 (SEQ. ID NO: 109) f1f2f3Kf5Df7Lf9f10Qf12f13f14 wherein the substituents are as defined in the specification.Type: GrantFiled: July 9, 2013Date of Patent: September 22, 2015Assignee: Amgen Inc.Inventors: Hosung Min, Hailing Hsu, Fei Xiong
-
Publication number: 20150175687Abstract: The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.Type: ApplicationFiled: October 30, 2014Publication date: June 25, 2015Inventors: Huiquan Han, Hosung Min, Thomas Charles Boone
-
Publication number: 20150044236Abstract: Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.Type: ApplicationFiled: May 22, 2014Publication date: February 12, 2015Applicant: AMGEN INC.Inventors: Kenneth W. WALKER, Yue-Sheng LI, Thomas Charles BOONE, HoSung MIN, Jane TALVENHEIMO, Taruna ARORA, Frederick W. JACOBSEN
-
Publication number: 20150044235Abstract: Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.Type: ApplicationFiled: May 22, 2014Publication date: February 12, 2015Applicant: Amgen Inc.Inventors: Kenneth W. WALKER, Yue-Sheng LI, Thomas Charles BOONE, George DOELLGAST (DECEASED), HoSung MIN, Jane TALVENHEIMO, Taruna ARORA, Frederick W. JACOBSEN
-
Patent number: 8920798Abstract: The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.Type: GrantFiled: November 20, 2012Date of Patent: December 30, 2014Assignee: Amgen Inc.Inventors: Huiquan Han, Hosung Min, Thomas Charles Boone
-
Publication number: 20140275479Abstract: Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.Type: ApplicationFiled: May 29, 2014Publication date: September 18, 2014Applicant: AMGEN INC.Inventors: Jonathan Daniel OLINER, Hosung MIN
-
Publication number: 20140234334Abstract: The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz2Lz4 wherein z2 is an amino acid residue and z4 is threonyl or isoleucyl. Exemplary molecules comprise a sequence of the formulae (SEQ. ID. NO: 100) a1a2a3CDa6La8a9a10Ca12a13a14, (SEQ. ID. NO: 104) b1b2b3Cb5b6Db8Lb10b11b12b13b14Cb16b17b18 (SEQ. ID. NO: 105) c1c2c3Cc5Dc7Lc9c10c11c12c13c14Cc16c17c18 (SEQ. ID. NO: 106) d1d2d3Cd5d6d7WDd10Ld13d14d15Ld16d17d18 (SEQ. ID. NO: 107) e1e2e3Ce5e6e7De9Le11Ke13Ce15e16e17e18 (SEQ. ID NO: 109) f1f2f3Kf5Df7Lf9f10Qf12f13f14 wherein the substituents are as defined in the specification.Type: ApplicationFiled: July 9, 2013Publication date: August 21, 2014Applicant: AMGEN INC.Inventors: Hosung MIN, Hailing HSU, Fei XIONG
-
Patent number: 8734796Abstract: Disclosed is an isolated antigen binding protein, such as but not limited to, an antibody or antibody fragment. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors, host cells, and hybridomas useful in methods of making it. In some embodiments the antigen binding protein comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.Type: GrantFiled: March 19, 2010Date of Patent: May 27, 2014Assignee: Amgen Inc.Inventors: Kenneth W. Walker, Yue-Sheng Li, Thomas C. Boone, Frederick W. Jacobsen, HoSung Min, Jane Talvenheimo, Taruna Arora, Janet Doellgast
-
Patent number: 8557543Abstract: A polypeptide inhibiting binding between vascular endothelial growth factor receptor-2 and a vascular endothelial growth factor, a fusion protein including the same, and a method of preparing the fusion protein are disclosed.Type: GrantFiled: December 20, 2010Date of Patent: October 15, 2013Assignee: Samsung Electronics Co., Ltd.Inventors: A-yeon Cho, Min-kyung Kim, Brian Hosung Min, Jong-sang Ryu
-
Patent number: 8541201Abstract: The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal.Type: GrantFiled: July 19, 2011Date of Patent: September 24, 2013Assignee: Amgen Inc.Inventors: Hosung Min, Kenneth W. Walker, Colin V. Gegg, Francesco Galimi, Jeonghoon Sun, Mei-Mei Tsai
-
Publication number: 20130230515Abstract: The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.Type: ApplicationFiled: November 20, 2012Publication date: September 5, 2013Applicant: AMGEN INC.Inventors: HQ HAN, HOSUNG MIN, THOMAS CHARLES BOONE
-
Patent number: 8507426Abstract: The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz2Lz4 wherein z2 is an amino acid residue and z4 is threonyl or isoleucyl. Exemplary molecules comprise a sequence of the formulae (SEQ?ID?NO:?100) a1a2a3CDa6La8a9a10Ca12a13a14, (SEQ?ID?NO:?104) b1b2b3Cb5b6Db8Lb10b11b12b13b14Cb16b17b18 (SEQ?ID?NO:?105) c1c2c3Cc5DC7Lc9c10c11c12c13c14Cc16c17c18 (SEQ?ID?NO:?106) d1d2d3Cd5d6d7WDd10Ld13d14d15Ld16d17d18 (SEQ?ID?NO:?107) e1e2e3Ce5e6e7De9Le11Ke13Ce15e16e17e18 (SEQ?ID?NO:?109) f1f2f3Kf5Df7Lf9f10Qf12f13f14 wherein the substituents are as defined in the specification.Type: GrantFiled: May 26, 2010Date of Patent: August 13, 2013Assignee: Amgen, Inc.Inventors: Hosung Min, Hailing Hsu, Fei Xiong